

Johannes studied medicine in Giessen, Heidelberg and Freiburg and obtained his doctoral degree (MD) from Heidelberg University in 2002. After a 6-year clinical residency at Heidelberg University Hospital, he conducted from 2003-2007 postdoctoral studies in the Department of Molecular Biology in Dallas at UT Southwestern. In 2007, he returned to Heidelberg and became an Emmy Noether Junior Research Group Leader and in 2013 Associate Professor. In 2015, Johannes was promoted to a Full Professor and became the Director of the Institute of Experimental Cardiology. Johannes is currently the spokesperson of the Collaborative Research Center 'Molecular Circuits of Heart Disease' (CRC-1550), Director (interim) of the Helmholtz Institute for Translational AngioCardioScience, and one founder of REVIER Therapeutics. Johannes' research is focused on a better understanding of the regulatory epigenetic mechanisms of heart disease and the translation towards novel therapies. Recently, Johannes's lab started to work on new therapeutic approaches for cardiometabolic disease.